A closer look at a patient who may be appropriate for YESCARTA
CAR T therapy
While information below is not from an actual patient and does not encompass all characteristics for YESCARTA eligibility, this profile is one example of the range of patients who may be candidates for YESCARTA.
Relapsed Stage IIIA FL
Age: 67 years
- Relapsed FL
- ECOG PS score 0; Ann Arbor stage IIIA; high-risk FLIPI
- High tumor burden based on GELF criteria
- Normal function of heart, lungs, liver, and kidneys
- Two prior therapies
- R-bendamustine: Relapsed following 1 year, 11 months in CR
- O-CHOP: Relapsed following 4 months in CR
YESCARTA treatment: personalized cell therapy built on close collaboration
Your role is essential in the YESCARTA treatment journey
Whether it’s before, during, or after treatment, the collaboration between the primary hematologist/oncologist and the YESCARTA Authorized Treatment Center (ATC) is critical to help give your patients the best possible care.
Early patient identification is critical to patient outcomes.3
It’s important to know when to consider YESCARTA because once a patient has been identified, specialist consultation can begin.
Specialist Consultation and Timely Access
Early consultation with a lymphoma specialist at an ATC allows for collective assessment of treatment options.3
Find a YESCARTA ATC to begin the consultation discussion.
If YESCARTA is right for the patient, the ATC may begin treatment.
Collaboration between primary hematologist/oncologist and the ATC ensures the best possible care.
~3 to 4 hours4: Lymphocytes are collected from the patient and then shipped to the manufacturing site.2
~17 days*: The patient’s T cells are isolated and engineered ex vivo at a state-of-the-art Kite facility to become CAR T cells.2
*Data reflect results from the ZUMA-5 pivotal trial. The median time from leukapheresis to product delivery.2
3 days (starting 5 days before YESCARTA infusion): The patient receives a lymphodepleting chemotherapy regimen.2
~30 minutes: A single infusion of YESCARTA is administered to the patient at the YESCARTA ATC.2
The patient is monitored at least daily for 7 days by the YESCARTA ATC for signs and symptoms of cytokine release syndrome, neurologic toxicities, and any other side effects.2
For at least 4 weeks after infusion: The patient should stay within 2 hours of the YESCARTA ATC.2,5
Ongoing Care and Follow-up
As your patient returns home after their CAR T therapy, they will require your long-term support and ongoing care. Follow-up appointments track the patient’s progress and monitor for adverse reactions. The primary hematologist/oncologist and ATC
should remain in contact regarding the patient’s progress.2
For 8 weeks after infusion: the patient should not drive, operate heavy machinery, or do other dangerous things because the treatment can cause sleepiness, confusion, weakness, and temporary memory and coordination problems.2
In addition to other adverse events, monitoring should include2:
- Prolonged cytopenias
- Secondary malignancies
- Serious infections
Please see full Prescribing Information for additional monitoring recommendations.
PROACTIVE PATIENT IDENTIFICATION
PROACTIVE PATIENT IDENTIFICATION IS CRITICAL TO OUTCOMES
While YESCARTA is indicated after ≥2 lines of systemic therapy, you can start identifying and educating your patients proactively in order to accelerate time between potential second-line failure and CAR T treatment.2
EARLY SPECIALIST CONSULTATION
CONSULT WITH A CAR T SPECIALIST AT AN AUTHORIZED TREATMENT CENTER THAT MEETS YOUR PATIENT’S NEEDS
Early consultation helps determine if YESCARTA is right for your patient and maximizes their chance at receiving therapy. The optimal time for a consultation may be as soon as first relapse to help ensure optimal access to all available treatment options.3 Consider telemedicine consultations, which may be covered by a patient’s insurance. Always check with the patient’s plan to confirm coverage.
YESCARTA is available only at ATCs with specialized CAR T healthcare teams trained on how to administer, monitor, and care for patients.2 Choice of an ATC is within the sole discretion of the treating physician and patient. Kite does not endorse any individual ATC.
MAXIMIZE YOUR PATIENT’S CHANCE AT RECEIVING YESCARTA
As soon as second-line treatment failure or relapse, patients can be evaluated for CAR T therapy at the ATC. Once assessed by the CAR T team, your qualified third-line patients can begin YESCARTA therapy.
Timely administration of CAR T therapy is critical
Kite is committed to providing fast turnaround times, in-spec target doses, and convenient apheresis date options to give patients a chance at realizing the benefits of YESCARTA.2
CAR=chimeric antigen receptor; CAR T=chimeric antigen receptor T cell; CR=complete remission; ECOG PS=Eastern Cooperative Oncology Group performance status; FL=follicular lymphoma; FLIPI=Follicular Lymphoma International Prognostic Index; GELF=Groupe d’Etude des Lymphomes Folliculaires; O-CHOP=obinutuzumab, cyclophosphamide, doxorubicin, prednisolone, vincristine; R=rituximab.
Refer eligible patients to a YESCARTA Authorized Treatment Center
Dedicated support throughout the treatment journey
References: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-Cell Lymphomas V.5.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed July 12, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. 2. YESCARTA® (axicabtagene ciloleucel). Prescribing information. Kite Pharma, Inc; 2022. 3. Jacobson CA, Farooq U, Ghobadi A. Axicabtagene ciloleucel, an anti-CD-19 chimeric antigen receptor T-cell therapy for relapsed or refractory large B-cell lymphoma: practical implications for the community oncologist. Oncologist. 2020;25(1):e138-e146. 4. Roberts ZJ, Better M, Bot A, et al. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL. Leuk Lymphoma. 2018;59(8):1785-1796. 5. YESCARTA® and TECARTUS® REMS Patient Wallet Card. REMS-CTF-0026. April 2021. 6. Data on file . Kite Pharma, Inc; 2022. 7. Data on file . Kite Pharma, Inc; 2022. 8. Data on file . Kite Pharma, Inc; 2022.